Literature DB >> 7562557

Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.

R A Mathôt1, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman, M Danhof.   

Abstract

The purpose of the present study was to quantify the in vivo potency of the selective adenosine A2a antagonist CSC [8-(3-chlorostyryl)caffeine]. Four groups of conscious, normotensive rats received a continuous i.v. infusion of 0, 6, 12 and 24 micrograms/min/kg of CSC. During a steady-state infusion of CSC, the animals received 1000 micrograms/kg of the adenosine A2a receptor agonist CGS 21680C [the sodium salt of 2-p-(2-carboxyethyl) phenylethylamino-5'-N-ethylcarboxamidoadenosine] i.v. over 15 min. During the experiment, the mean arterial pressure and the heart rate were recorded continuously and arterial blood samples were taken for the analysis of drug concentrations. For each individual rat, the CGS 21680C-provoked reduction in blood pressure was related to the blood concentration of the agonist according to the sigmoidal Emax model. The presence of CSC produced a parallel shift of the concentration-hypotensive effect curve to the right, indicating competitive interaction of the compounds. Infusion of 0, 6, 12 and 24 micrograms/min/kg of CSC resulted in steady-state concentrations of 0, 85 +/- 7, 210 +/- 20 and 400 +/- 40 ng/ml, and apparent EC50 values of CGS 21680C based on free concentrations (EC50,u) of 4.8 +/- 1.1, 7.2 +/- 0.5, 32 +/- 6 and 57 +/- 10 ng/ml, respectively (mean +/- S.E., n = 6, 6, 5 and 6). The relationship between the CSC concentration and the apparent EC50 was quantified according to a competitive pharmacodynamic interaction model.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562557      PMCID: PMC5473028     

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.

Authors:  J Shimada; F Suzuki; H Nonaka; A Ishii; S Ichikawa
Journal:  J Med Chem       Date:  1992-06-12       Impact factor: 7.446

2.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

3.  Cardiovascular effects of adenosine A2 agonists in the conscious spontaneously hypertensive rat: a comparative study of three structurally distinct ligands.

Authors:  R L Webb; B W Barclay; S C Graybill
Journal:  J Pharmacol Exp Ther       Date:  1991-12       Impact factor: 4.030

Review 4.  Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

Authors:  J Linden
Journal:  Trends Pharmacol Sci       Date:  1994-08       Impact factor: 14.819

5.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 6.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

7.  The antihypertensive effect of 2-alkynyladenosines and their selective affinity for adenosine A2 receptors.

Authors:  T Abiru; T Yamaguchi; Y Watanabe; K Kogi; K Aihara; A Matsuda
Journal:  Eur J Pharmacol       Date:  1991-04-10       Impact factor: 4.432

8.  Liquid chromatographic determination of the adenosine receptor agonist CGS 21680 in blood using on-line solid-phase extraction on a phenylboronic acid support and fluorescence detection.

Authors:  H Irth; A Cleton; R A Mathôt; M Danhof; A P IJzerman; U R Tjaden; J van der Greef
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-05

9.  Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.

Authors:  R A Mathôt; E A van Schaick; M W Langemeijer; W Soudijn; D D Breimer; A P Ijzerman; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

Review 10.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

View more
  3 in total

1.  Continuous adenosine A2A receptor antagonism after focal cerebral ischemia in spontaneously hypertensive rats.

Authors:  Ulrike Fronz; Alexander Deten; Frank Baumann; Alexander Kranz; Sarah Weidlich; Wolfgang Härtig; Karen Nieber; Johannes Boltze; Daniel-Christoph Wagner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-10-30       Impact factor: 3.000

2.  Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists.

Authors:  Charles W Schindler; Marzena Karcz-Kubicha; Eric B Thorndike; Christa E Müller; Srihari R Tella; Sergi Ferré; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

3.  Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo.

Authors:  R A Mathoôt; W Soudijn; D D Breimer; A P Ijzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.